Human Gut Microbiome and Cardiometabolic Disease
This webinar is Part 2 of the three-part Microbiome Webinar Series. In this webinar, you will learn:
- Current knowledge of the human gut microbiome
- The role of the gut microbiome in cardiometabolic disease
- How fecal microbiota transplantation can treat disease
Summary
The gut microbiome, a large and complex community of microorganisms including bacteria, fungi and viruses, has been extensively associated with human health and development of disease. Humans with metabolic syndrome and type 2 diabetes (together cardiometabolic disease, CMD) for example, have an altered gut microbiome composition. In addition, not only the microorganism and their structural components but also their metabolites influence human metabolism and might alter CMD.
Although the field is dominated by association studies, data on a causal role of the gut microbiome in human disease development have emerged in the past years. For example, our group has shown that modulation of the gut microbial composition by fecal microbiota transplantation (FMT) from lean, healthy donors improves insulin sensitivity in insulin resistant recipients. These studies implicate that targeting the gut microbiome holds merit to serve as preventive measure for development of CMD or to lower the burden on those already affected. Importantly, there is a significant knowledge gap in factors determining gut microbiota composition and function and interaction with human metabolism. In this webinar, I will provide a birds eye view on current standings on the role of the gut microbiome, including lessons from FMT, in human CMD.
Other webinars in this series:
Automated Sample Preparation for Fecal Microbiome Samples
Systems Genetics Approaches Uncover Microbe-Lipid-Host Connections in the Murine Gut
Speaker
Hilde Herrema, PhD
Medical Biologist
Amsterdam University Medical Center
The Netherlands
Hilde Herrema is a medical biologist with specific molecular and systemic expertise on development of cardiometabolic diseases in obesity, in particular diabetes and fatty liver disease. After her postdoc at Harvard Medical School (Boston, USA), she joined the group of Prof. Nieuwdorp (AMC) to study the role of the gut microbiome in the complex pathophysiology of diabetes and fatty liver disease. She is currently junior group leader and uses a translational and multidisciplinary approach to study cardiometabolic disease development, with a particular focus on gut bacteriophages (viruses of bacteria) and their role in gut microbiome function and human health.